Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors.
Cancer is an important threat to public health because of its high morbidity and mortality. In recent decades, immune checkpoint inhibitors (ICIs) have ushered a new therapeutic era in clinical oncology. The rapid development of immune checkpoint therapy is due to its inspiring clinical efficacy in a group of cancer types. Metformin, an effective agent for the management of type 2 diabetes mellitus (T2DM), has shown beneficial effects on cancer prevention and cancer treatment. Emerging studies have suggested that metformin in combination with ICI treatment could improve the anticancer effects of ICIs. Hence, we conducted a review to summarize the effects of metformin on ICI therapy. We also review the pleiotropic mechanisms of metformin combined with ICIs in cancer therapy, including its direct and indirect effects on the host immune system.
['Liu|Wenhui|W|', 'Wang|Ying|Y|', 'Luo|Jianquan|J|', 'Liu|Mouze|M|', 'Luo|Zhiying|Z|']
D000818:Animals D006801:Humans D000082082:Immune Checkpoint Inhibitors D008687:Metformin D009369:Neoplasms
pleiotropic metformin PD-1 PD-L1 gut microbiome immune check inhibitors